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A
	 What	risk	factors	contribute		
to	C difficile diarrhea?
	 certain antibiotics and using
 3 or more antibiotics at one 
time	 are	 associated	 with	 Clostridium 
difficile-associated	 diarrhea	 (CDAD)	
(strength	 of	 recommendation	 [SOR]:	 B,	
1	 heterogeneous	 systematic	 review	 and	
several	good-quality	cohort	studies).	
Hospital	risk	factors	include	proximity	
to	other	patients	with	C difficile	and	longer	
length	of	stay	(SOR:	B,	several	good-quality	
cohort	studies).	
Patient	 risk	 factors	 include	 advanced	
age	and	comorbid	conditions	(SOR:	B,	sev-
eral	good-quality	cohort	studies).	
Acid	suppression	medication	 is	also	a	
risk	 factor	 for	CDAD	(SOR:	B,	 1	heteroge-
neous	systematic	review	and	2	good-quality	
cohort	studies).
Evidence summary
One	 systematic	 review	 found	 increased	 risk	
of	 CDAD	 in	 patients	 taking	 cephalosporins,	
penicillin,	or	clindamycin	 (tABLE 1).1	A	sub-
sequent	 retrospective	 cohort	 investigation	
of	5619	patients	during	a	CDAD	epidemic	in	
Quebec,	Canada	reported	that	quinolone	an-
tibiotics	were	most	 strongly	 associated	with	
CDAD,	 whereas	 other	 antibiotics	 posed	 an	
intermediate	risk.2	
A	 prospective	 cohort	 study	 of	 101,796	
admissions	over	a	5-year	period	at	a	tertiary	
medical	 center	 defined	 a	 group	of	 high-risk	
antibiotics	before	starting	research.3	They	in-
cluded	fluoroquinolones,	cephalosporins,	in-
travenous	 b-lactam/b-lactamase	 inhibitors,	
macrolides,	clindamycin,	and	carbapenems.	
All	other	antibiotics	were	considered	low	risk.	
High-risk	 antibiotics	 were	 associated	 with	
a	 3-fold	 increase	 in	 CDAD	 compared	 with	
low-risk	 drugs	 (odds	 ratio	 [OR]=3.37;	 95%	
confidence	 interval	 [CI],	 2.64-4.31);	 number	
needed	to	harm	[NNH]=	10).3	
the number of antibiotics 
is a factor 
The	number	of	antibiotics	used	also	may	influ-
ence	the	risk	of	CDAD.	A	retrospective	cohort	
of	 2859	 patients	 from	 a	 community	 hospital	
found	that	an	increased	number	of	antibiotics	
was	a	risk	factor	for	CDAD	(OR=1.49;	95%	CI,	
1.23-1.81;	 NNH=44).4	 Another	 retrospective	
cohort	study	of	1187	inpatients	at	a	Montreal	
hospital	found	3	or	more	antibiotics	increased	
the	 risk	 (adjusted	 OR=2.1;	 95%	 CI,	 1.3-3.4;	
NNH=20).5	
 Hospital risks: Proximity to an infected 
patient, length of stay
A	prospective	cohort	of	252	patients	and	a	ret-
rospective	 cohort	 of	 1187	 patients	 show	 that	
recent	hospitalization	puts	patients	at	risk	for	
CDAD	 (tABLE 2).5,6	 Several	 retrospective	 co-
hort	studies	have	shown	that	patients	in	close	
proximity	 to	 a	 C difficile−positive	 patient	 in	
the	 hospital	 (roommate,	 neighbor,	 or	 subse-
quent	tenant)	are	at	risk	for	CDAD.4,7	
Length	 of	 hospitalization	 is	 also	 a	 risk	
factor.2	 A	 retrospective	 cohort	 study	 of	 2859	
patients	 found	that	patients	with	CDAD	had	
spent	more	 time	 in	 the	hospital—a	mean	of	
19	 days	 compared	 with	 8	 days	 for	 patients	
without	 diarrhea	 (P<.001).4	 A	 prospective	
cohort	 study	 of	 101,796	 admissions	 report-
ed	 that	 the	mean	 length	of	 stay	was	15	days	
(range=8.0-26.0)	 for	 CDAD	 patients	 com-
pared	with	5	days	(range=3.0-8.0)	for	patients	
without	CDAD	(P<.001).3	
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Certain 
antibiotics, 
using 3 or more 
antibiotics at a 
time, and acid 
suppression 
medications 
are associated 
with C difficile 
diarrhea. 
Patient risk factors:  
Age and comorbid disease
Two	cohort	studies	found	that	CDAD	patients	
were	about	10	years	older	than	patients	with-
out	 CDAD.3,8	 Among	 535	 patients	 in	 Jerusa-
lem,	patients	positive	for	C difficile	toxin	had	
a	 mean	 age	 of	 76±20	 years	 compared	 with	
66±26	 years	 in	 toxin-negative	 patients	
tABLE 1 
Medications	associated	with	C difficile	diarrhea
medication Reported ratio* (95% cI) NNh†
Antibiotics 
b-lactam/b-lactamase inhibitor, intraveneous2 ahR=1.88 (1.35-2.63) 25
cephalosporins1 RR=2.07 (1.06-6.62) 21
cephalosporins, first generation2 ahR=1.78 (1.28-2.46) 28
cephalosporins, second generation2 ahR=1.89 (1.45-2.46) 25
cephalosporins, third generation2 ahR=1.56 (1.15-2.12) 39
clindamycin1 oR=4.22 (2.11-8.45) 8
clindamycin2 ahR=1.77 (1.06-2.96) 28
macrolides2 ahR=1.65 (1.15-2.39) 33
Penicillins1 RR=3.62 (1.28-8.42) 9
Quinolones2 ahR=3.44 (2.65-4.47) 10
Acid suppression medication
histamine2-receptor antagonist3 aoR=1.53 (1.12-2.10) 41
Proton-pump inhibitor daily3 aoR=1.74 (1.29-2.18) 30
Proton-pump inhibitor more often than daily3 aoR=2.36 (1.79-3.11) 17
ahR, adjusted hazard ratio; aoR, adjusted odds ratio; cI, confidence interval; NNh, number needed to harm; oR, odds ratio; 
RR, risk ratio.
*Because the incidence of C difficile diarrhea is low, each reported adjusted hazard ratio or risk ratio is approximately equal 
to the odds ratio used to calculate number needed to harm.
†assuming an event rate of 5%.
tABLE 2 
Hospital	risk	factors	for	C difficile	diarrhea
hospital factor Reported ratio* (95% cI) NNh† 
length of stay 4-7 vs 1-3 days2 hR=4.69 (2.14-10.28) 6
length of stay 8-14 vs 1-3 days2 hR=5.11 (2.34-11.18) 6
length of stay >15 vs 1-3 days2 hR=3.55 (1.53-7.24) 10
any proximity to cdad-positive patients4 RR=3.34 (2.00-5.57) 10
admission within previous 3 months5 oR=3.0 (1.5-6.0) 11
admission within previous 30 days6 oR= 2.6 (1.13-5.7) 14
cdad-positive patient in adjacent bed7 oR=2.34 (1.56-3.51) 17
occupying bed of previous cdad-positive patient7 oR-2.33 (1.54-3.52) 17
cdad, Clostridium difficile-associated diarrhea; cI, confidence interval; hR, hazard ratio; NNh, number needed to harm; 
oR, odds ratio; RR, relative risk.
*Because the incidence of C difficile diarrhea is low, each reported hazard ratio or risk ratio is approximately equal to the 
odds ratio, which was used to calculate number needed to harm.
†assuming an event rate of 5%.
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(P<.001).8	 In	 the	 previously	 mentioned	
study	 of	 101,796	 patients,	 the	 average	 age	
for	patients	with	CDAD	was	65.4±16.9	 years	
compared	 with	 56.5±19.9	 years	 for	 patients	
without	CDAD	(P<.001).3	
The	 patients	 in	 this	 study	 also	 showed	
significant	 associations	 between	 CDAD	 and	
comorbid	 conditions,	 including	 myocardial	
infarction,	 heart	 failure,	 chronic	 pulmonary	
disease,	peripheral	vascular	disease,	compli-
cated	diabetes,	fluid	and	electrolyte	disorders,	
chronic	 renal	 failure,	 cancer,	 coagulopathy,	
and	methicillin-resistant	Staphylococcus au-
reus infection.3	
 Acid suppression therapy 
is another risk
A	 systematic	 review	 that	 included	 a	 total	 of	
2948	 patients	 in	 12	 studies	 (cross-sectional,	
case-control,	 and	 cohort)	 evaluated	 acid	
suppression	 therapy	 and	 found	 an	 associa-
tion	 between	CDAD	 and	 use	 of	 histamine2-
receptor	 antagonists	 (H2RAs)	 (OR=1.48;	
95%	 CI,	 1.06-2.06;	 NNH=45)	 and	 between	
CDAD	 and	 proton-pump	 inhibitors	 (PPIs)	
(OR=2.05;	95%	CI,	1.47-2.85;	NNH=21).9	Sig-
nificant	heterogeneity	among	the	studies	lim-
ited	the	interpretation	of	results,	however.	
The	prospective	cohort	study	of	101,796	
patients	 also	 reported	 an	 increased	 risk	 of	
CDAD	 with	 H2RAs	 and	 PPIs.3	 The	 risk	 of	
CDAD	 rose	 with	 progression	 from	 no	 acid	
suppression	 to	H2RA	use	 to	daily	PPI	use	 to	
more	frequent	PPI	use.3	Another	cohort	study	
of	 1187	 patients	 found	 an	 association	 be-
tween	PPIs	and	CDAD	(adjusted	OR=2.1;	95%	
CI,	1.2-3.5).5	
Using a score to gauge risk 
Researchers	 studying	 a	 cohort	 of	 54,226	 pa-
tients	 developed	 a	 risk	 score	 using	 clinical	
characteristics	 associated	 with	 CDAD.10	 The	
patients	 were	 older	 than	 18	 years,	 hospital-
ized	 longer	 than	 48	 hours,	 and	 had	 received	
broad	 spectrum	 antibiotics	 (intravenous	 gly-
copeptides,	 fluoroquinolones,	 penicillins,	
cephalosporins,	 or	 carbapenems).	When	 the	
researchers	tested	their	clinical	risk	index	on	a	
validation	cohort	of	13,002	patients,	they	found	
that	increasing	scores	were	significantly	asso-
ciated	with	increasing	risk	for	C difficile	colitis	
(OR=3.31;	95%	CI,	2.61-4.91;	area	under	the	re-
ceiver	operating	characteristic	curve=0.712).10	
Recommendations
Clinical	practice	guidelines	by	the	Society	for	
Healthcare	Epidemiology	of	America	and	the	
Infectious	 Diseases	 Society	 of	 America	 rec-
ommend	minimizing	the	frequency	and	du-
ration	of	antibiotics	and	the	total	number	of	
antibiotics	 used.11	They	 also	 suggest	 private	
rooms,	chlorine	cleaning	products,	and	con-
tact	 precautions	 (gloves,	 hand	 hygiene,	 and	
disposable	thermometers)	to	reduce	risk.	
The	authors	of	the	guidelines	propose	an-
timicrobial	stewardship	programs	based	on	the	
local	epidemiology	of	C difficile	strains,	includ-
ing	restricted	use	of	cephalosporins	and	clinda-
mycin,	except	for	surgical	prophylaxis.													JFP
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